VALLONE REPORT

Special Edition:
MedTech Visionaries
2021

VR

Welcome to a special issue of the Vallone Report, MedTech Visionaries the Best in the Industry.

We'd like to bring recognition to the outstanding individuals and companies whose ongoing contributions to society, through various sectors including the arts and sciences, cannot be overestimated!

The MedTech Visionaries Awards, hosted by Light4Soul to honor the leaders, businesses and individuals who stand out in this field.

It is an honor to present those chosen to be honored as the Best Leaders in their Industry. And it is our distinct pleasure to provide a glimpse into the judges who have such distinguished careers in this sector.

Lisa O'Keefe

LISA O'KEEFE

MARKETING DIRECTOR MEDTECH VISIONARIES AWARDS

TABLE OF CONTENTS

Editor: Lisa O'Keefe

Advertising: Grant Butler

E-mail leftbrain@light4soul.com

Innovation distinguishes between a leader and a follower ~ Steve Jobs

They say it is risky to challenge the status quo but for the 'Newtonian' leaders in the technology realm they believe it is riskier to maintain it. For you see, according to Newton's 1st law, 'status quo' can easily be seen as the object at rest and remains at rest until compelled to change. And change it must for our society, our world, our problems are becoming increasingly complex by the moment and demands that technology not only keep pace in addressing its needs but also expects it to predict its wants for the future we all envision.

Status quo can never move anything forward. It depends on those brave enough to disrupt the present circumstances to effectuate positive change. And these people who make a conscious choice to move an object into motion and keep it in motion are worthy of our recognition and our gratitude.

With that said, the MedTech Visionaries Awards is proud to have provided a platform from which to provide recognition and increased visibility to a sector that continues to make a positive impact in how we view our world and interact with it. The event was hosted by the creative strategist people at Light4Soul and was sponsored by iamYiam and Boost Awards. This year's awards saw entries from around the world who have set the standard for innovation and creativity in the MedTech field. Their entries were reviewed and judged by our panel of experts in the MedTech field including those in the field of AR/VR, medical devices, wearables, hospital implementation, technology marketing, journalism and strategic counseling. It was the judge's task to choose, among the entries, those companies and individuals that truly deserve recognition as leaders for the advancement of technology for the benefit of society. It is Light4Soul's distinct pleasure to give you a glimpse into the people worthy of recognition - those who have not allowed 'status quo' to be a constant.

JEFFREY ZINK

VP Sales Business Development -4th Bin | Strategic Planning | Revenue Enhancements / Westchester Angel Group Investor

Jeffrey is a nationally syndicated speaker with over 30 years of experience in launching new businesses, turnarounds, and business acceleration. Jeffrey serves as a Board of Advisor for several startup companies. Jeffrey is an experienced angel investor who is intimately involved in several industries.

Check out the 4th Bin booth on MedTech Visionaries

PETR ŠRÁMEK

Managing Partner at LongevityTech.fund; CEO of Whytics

Petr is a serial entrepreneur, CEO of Whytics with a focus on counterfactual simulations using brain-inspired AI and the latest advances in counterfactual learning and causal emergence,as well as managing partner for LongevityTech.fund.

CareJourney

JOE MERCADO

Product Strategy & Design at CareJourney

Joe's exceptional levels of creative thinking and problem-solving, as well as an entrepreneurial mindset, enables excitement within his product development teams. Passionate about interoperability and transforming healthcare within the Population Health and Behavioral Health spaces, Joe is excited to continue pushing the envelope.

SUZANNE LEE

Founder of Pivotal Reality

Pivotal Reality's purpose is to research the social impact of using Virtual Reality, Augmented Reality, and Mixed Reality within target markets. Their first project is testing and measuring the effects of Virtual Reality and Dementia. They are the 2020 winners of the Mental Health Immersive Technology Consult MedTech Visionaries Awards.

IS YOUR REPUTATION ON GOOGLE STUCK ON JUST OK?

OK is OK... but in today's market with the speed of change so many more tech companies are entering the market.

That makes it harder to get that next stage of venture capital, in securing that grant, or getting entryway into a healthcare client...

So if you're not showing up on the first page of Google searches then maybe you should be coming to us...

Who are we?
We're **Light4Soul** and we
STRENGTHEN REPUTATIONS!

CONTACT
GRANTBUTLER@LIGHT4SOUL.COM
AND SEE HOW WE CAN HELP



LIGHT4SOUL

IS PROUD TO PRESENT

THE 2021 MEDTECH

VISIONARIES AWARD WINNERS

Out of Respiratory Need Comes Inspiration, Invention, and Adoption

Breathe in. Breathe out.

Such a simple exercise for me and you that we probably take this organ functioning for granted. But for more than a billion people globally each day who suffer from acute or chronic respiratory conditions brought on by genetics, disease, environment or COVID the health of their lungs is a constant struggle.

Enter Dymedso.

Dymedso is the MVA's 2021 winner of the Best MedTech Medical Device in the Respiratory Field.

Dymedso, a pioneer in using sound to treat patients with severe lung disorders and respiratory diseases, was founded by Yon Robert and Louis Plante, a Cystic Fibrosis patient. The idea came from a curious reaction at a concert, a reaction that got the ball rolling and set the ground work for Dymedso to be a true visionary in the MedTech Field. "Louis was a patient looking for solution to help his condition, and one night he was attending a conference in a concert hall and sitting next to a larger subwoofer when one of the participants in the conference was talking and Louis started coughing a lot and his mother said he was disturbing everyone around him. Louis was an electronic technician and he wondered why he got that reaction. His mother was a nurse who performed traditional clapping for Louis but he never got that same result as he did that night. So he started working on a prototype to develop a sound acoustic wave device that ended up being the Frequencer" stated Kim Anderson the President of Dymedso.

"From that Dymedso's vision has been to help deliver better care and helping to save as many lives as is possible using acoustic sound wave to clear the airways and promote bronchial drainage for people with pulmonary disorders and conditions by inducing vibration through the chest walls. The Frequencer provides no invasive technology. Rather through changing the capacity of music, it dislodges the mucus to unblock the airway. This allows the patient to breathe easier. The treatment is so gentle. We were able to treat any type of patient from across the hospital like a neonatal pediatric patient, convalescent patient on a respirator or ventilator therapy, elderly frail patients, transplant patient, patients with cystic fibrosis, chronic bronchitis, bronchiectasis, ciliary dyskinesia syndromes, asthma, muscular dystrophy, neuromuscular degenerative disorders, post-operative atelectasis and thoracic wall defects. The list goes on and on".

Kim Anderson, President of Dymedso further states, "We are committed to improving patient care while helping to save lives. As a result of the pandemic, this has extended to treating the airway clearance challenges associated with COVID-19, including superimposed pneumonia and acute respiratory distress (ARDS). And as the virus continues to evolve, our device will be used to treat infant and pediatric patients that are contracting COVID-19 and patients impacted by long-term respiratory complications which could require lung rehabilitation."

Visit dymedso at https://dymedso.com

The Frequencer®, is approved by Health Canada and the U.S. Food and Drug Administration (FDA) and is used by leading hospitals in more than 53 countries.

OWKIN MAKING MEDICAL RESEARCH COLLABORATIVE, INCLUSIVE AND PRIVACY PRESERVING

Owkin, the 2021 MVA winner of the Best MedTech Company in the Field of Oncology AI for Precision Medicine, was founded in 2016 by Thomas Clozel, MD, a clinical research doctor and former assistant professor in clinical hematology and by Gilles Wainrib, PhD, an academic pioneer in the field of Artificial Intelligence in biology with the goal of improving drug development and patient outcomes. The company was built on the belief that medical research should be collaborative, inclusive, and privacy-preserving. Today, Owkin is building a global research network — using federated learning - connecting data scientists, clinicians, researchers, and pharma on a research platform that keeps the data secure and preserves privacy. Asif Jan, Head of Platform and Solutions states that "Our mission is to find treatments for every patients, starting off in oncology but spreading out to other unmet medical needs and we do so by bringing the power of data and AI and medical expertise together and essentially coming up with novel insights that would essentially be the foundation of building our new clinical programs, new drugs and new diagnostic tools as well it would aid in implementing new strategies for managing patients in clinical hospitals and other settings."

Asif states that it is a co mmon understanding that in healthcare today access to more data will help us understand the disease better and therefore novel treatments and diagnostic tools could be implemented into the real world. But today the data is fragmented and spread all over the place. "So, we started off with the belief that data is so foundational to improving patient care and improving research and we need to build an infrastructure to bring it all together. First and foremost, what we are building out is a technology infrastructure to link together information across different multiple institutes while respecting ownership data residency and ownership – it means the data doesn't have to leave the hospital in order to be used in an algorithm and that is revolutionary. We have essentially built a triangle of technology, medical expertise and data which can find new targets that one could subsequently feed into R&D and new diagnostic tools that could be deployed in the diagnostic platforms that are already being used in the hospitals."

Asif adds that the approach is toward responsible use of data and breaking the silos between data science and medical communities. Traditionally these communities have collaborated in their own circles but with Owkin once they have connected the dots from a data perspective then the two communities are brought together in a collaborative manner to maximize the use of data while keeping the data privacy and institutional ownership and leveraging the data with an existing institution and country.

As the world responds to COVID-19, speed, and collaboration in clinical research has never been more important. Owkin's collective race to understand and discover treatments for this threat to society offers unprecedented opportunities to improve the field of medical research from every angle.

OWKIN

UNPRECEDENTED COLLABORATIONS FOR PRECISION MEDICINE

https://owkin.com/

Go to Google and type in the words “modern stethoscope” — and as Gomer Pyle would say “Surprise, Surprise, Surprise”.

The entry directs you to Rene Laennec, a French physician who, in 1816, invented the stethoscope.

> *Well Google you are dating yourself because although the stethoscopes used throughout time have only received minor updates since the 1930s they haven't advanced in their functionality to perform auscultation and identify sounds until NOW!*

Enter Thinklabs One Digital Stethoscope . . . **the winner of the MedTech Visionaries 2021 "Best MedTech Use in the Field of Cardiology"** category. It is the invention of Thinklabs Medical's CEO and Founder Clive Smith. The Digital Stethoscope is the smallest, clearest sounding stethoscope in the world being able to amplify more than one hundred times making it possible to hear in noisy environments such as ambulances, ER rooms or through people's clothes and those who are difficult to auscultate. And it has high performance earbud headphones and various sized ear clips, a fully adjustable volume for ease of listening and the ability to adjust the range of frequencies and the frequency response. The Thinklabs One can be connected to extension cables or wireless speakers and headphones, enabling clinicians to be physically distant from infectious patients during the COVID-19 pandemic. Smith has been thinking about stethoscope design and acoustics since 1991, when he founded Thinklabs. Now more than ever, the Thinklabs One stethoscope has proven to be critical in helping to mitigate the spread of infectious diseases, such as Ebola and now, Covid-19.

But the Thinklabs One Digital Stethoscope is more than that. It is the future of telemedicine with its app that connects the stethoscope to a smartphone thereby allowing the doctor to store the sounds anywhere and to anyone. Now the sounds can be stored in a patient's records so it can be analyzed and compared at a later date against more recent recordings or it can be sent to another doctor for their records or for a second opinion. This device has now been implemented in some of the world's most prestigious medical facilities (Johns Hopkins, Brigham and Women's, NHS, and many others), Smith's invention has helped keep countless healthcare workers safe during the pandemic via Safe Distance Auscultation™, which allows practitioners to listen to patients' hearts and lungs from a safe distance with the use of Bluetooth speakers or headphones, or headphones that can be used with PPE. Smith was also on the frontline with healthcare workers in past pandemics, including Ebola and SARS, and has witnessed how his innovation can help keep clinicians safe while they care for these highly infectious patients. Not only has Clive always been a futuristic thinker, he has dedicated his career to medical technology that protects the lives of healthcare workers, proving himself to truly be one of MedTech's finest visionaries.

Its time to throw away the limited use and outdated hollow tube designed stethoscopes and upgrade to this sleek looking, powerful device that is small enough to fit into the palm of your hand.

Thinklabs
https://www.thinklabs.com/

Revolutionizing the field of bypass surgery and other procedures in the medical field

It is my pleasure to introduce you to one of the giants in the field of MedTech, a man who has made his life's mission about helping others and has advanced that mission into his company, SS Innovations, the 2021 MVA winner of the Best MedTech Robotic Company in the Field of Minimal Access Surgery.

Chairman, Founder and CEO, Dr. Sudhir Prem Srivastava's accomplishments include the fact that he performed the world's first single vessel beating heart TECAB in the United States. He also performed two world's first double and triple vessel TECAB on a beating heart and is the only person in the world to have performed a quadruple vessel beating heart TECAB. He has performed over 1400 robotic cardiothoracic surgeries, including 735 beating heart TECAB cases that represents the largest experience in the world. As one of the world's leading experts in robotic surgery, he is frequently an invited speaker for various national, international scientific meetings. And it is that expertise that guided him to developing what others are deeming something far more advanced and beneficial than any other product on the market today including the DaVinci.

Dr. Sudhir Prem Srivastava stated that SS Innovations mission was "to create a new, technologically advanced system that would leapfrog the existing surgical robotic systems and be very cost effective to benefit many more patients around the world. Disease does not discriminate against region, race, age and economic status of a person. Innovation and technologies, if not cost effective, will not benefit most. Advanced technologies and techniques should have global reach and not just rich economies. We must change direction of surgery with advances in technologies."

With SS Innovations robotic arms, yes arms in the plural, there is no longer a need to crack open sternum like is the standard procedure for over 99 percent of the bypass surgeries, but rather just a tiny incision needs to be made which leaves a minimal scar and helps with not only cost but with recovery time as well – in most cases advancing recovery to 3 or 4 weeks rather than months.

"You know, many physicians have ignored the fact that ultimately, whatever we are doing is to get patients back to their previous lifestyle so they can live as they did before. Our robotics do just that. We are technologically very different. Our cost will be 1/3 to ¼ the cost of the DaVinci XI system and we will offer more specialties. We are more comprehensive. No other robotic company is touching cardiac surgeries because of the complexities but with my background of doing over 1400 cardiac cases and with the knowledgeable and esteemed advisory board, SS Innovations will revolutionize cardiac and other specialties such as neurology, gynecology and more.

SS Innovations has finished first pilot human trials in India. They are now setting up manufacturing. As early as the end of this year there will be massive center global trials. SS Innovations has over 100 letters of intent from companies around the world including NYU and Columbia that are keenly interested in their product.

SS INNOVATIONS

https://ssinnovations.com/



Medix's long-term vision to develop and bring to market a range of better medical devices that support the immune system

I had the opportunity to speak with one of the most inspirational men of this century – not only for the groundbreaking product that is soon to be in the marketplace but for his never give up attitude and the belief that at any age someone can rock this world.

His name is Sol Gersh, a serial entrepreneur and the CEO of Medix the MVA 2021 winner for Best Visionary in the Field of Medical Devices in recognition of their immune-boosting products. But you may know this very young 95 year old's name from one of the many products he invented or companies he helped to get bought out.

He's a different breed – a man who has great ideas and knows how to get them to market. And Medix, which was founded in 2018 as a medical solutions company whose mission is to use its proprietary immune-boosting technology to improve the state-of-the-art of over-the-counter nasal inhalers and atomizers, is the next big idea – a company with an idea that will help those suffering from COPD, COVID and other illness or health issues. And this idea is something that has been close to his heart for many years. You see Sol lost his father at a vey young age from COPD, the third largest cause of death in the world. And after 100s of hours of research he had an epiphany. He found that one of the definitions for the word "medic" references plants with medical properties like aspirin that come from willow bark. And there were 90 or so plants that have been used for thousands of years starting in Egypt and being inhaled for medical purposes and these plants are used in 80 percent of the world to treat ailments with no side effects. One of the ingredients in Sol's inhaler is from a plant used to treat respiratory and the second ingredient is an antioxidant used to treat COPD. And these ingredients are edible, natural, organic and kosher. Plus the cost of using the inhaler is just a fraction of the cost for using Flonase or another name brand inhalers. Mr. Gersh said, "Our inhaler and atomizer are unique because they are reusable, cleaner, safer, healthier, and more cost-effective than the competition.

Medix's long-term vision is to develop and bring to market a range of better medical devices that support the immune system and deliver organic material, such as next-generation chest rubs. Medix is currently investment fund raising their seed round to begin the process of commercializing their products."

Medix
Organic Immune-Boosting Innovations
Visit www.medixinhaler.com

Todays inspiration comes from an interview I had with Dr, Kini from Mount Sinai hospital who reminded me that every second matters.

Every second matters

Dr. Annapoorna Kini: Is a Professor of Medicine at Mount Sinai's Icahn School of Medicine and the Director of the Cardiac Catheterization Laboratory at the Mount Sinai Medical Center. She is internationally recognized as a leader in the field of percutaneous coronary intervention and heart valve therapy and perform over 1,000 coronary interventions annually, the highest number by a female interventionist in the US, with an extremely low complication rate of 0.3%.

Dr. Annapoorna Kini MedTech Visionaries 2021 winner of the Best Apps & Software in Cardiology.

The iPhone/Android apps that the judges considered were those created by Dr. Kini to help in the many areas of complex intervention cardiology procedures. They are (1) the BifurcAID on treatment coronary bifurcation lesions utilizing systematic decision-making algorithms (2) the OCTAID on how to perform and interpret optical cohesion tomography imaging during coronary interventions (3) the TranseptAID on how to safely transverse the interatrial septum (4) the TAVRCathAID on how to efficiently perform coronary angiography through the struts of TAVR valve frames and (5) CalcificAID, an educational tool for treatment of calcific lesions. These Apps are developed in collaboration with her fellows and the Mount Sinai App-lab and available for free download the iTunes or Google Play Stores.

The judges were also impressed with vision set forth by Dr. Kini where free and readily available access to educational tools for assisting in the training of interventional cardiologists can be achieved around the globe. Through rigorous development and testing of these apps, hopefully that goal can be achieved and those who wouldn't have easy access to such innovations will be able to find a world of information and training techniques at their fingertips. Medicine is an international community. Developments in any country should always be shared with the others in order to improve the quality of life of all peoples, regardless of race, religion or creed.

Featured work can be found here:

- https://ccclivecases.org/
- https://cardiologyapps.com/
- https://www.doctorkini.com/
- https://cardiologyapps.com/stemicathaid/

Dr. Annapoorna Kini Linkedin

Building the future of healthcare with AI with Unified Automation

Have you heard of AKASA? If you haven't, you soon will as they are quickly gaining attention throughout the United States with various accomplishments and awards including being the 2021 MedTech Visionaries winner for the Best Apps and Software for Automated Healthcare RCM. And what makes this company really stand out is not only do they utilize the same machine learning that is used with driverless cars, but they combine it with subject matter expertise and the human element to make judgments that are needed to solve systemic issues in the back end of healthcare - modernizing the infrastructure of healthcare to reduce administrative costs often passed onto the patient.

"Our mission is to remedy the financial complexity crippling healthcare in America through Unified Automation™" said AKASA Co-Founder and CTO Varun Ganapathi, PhD. "We want to create a better future for health care using artificial intelligence and machine learning. And our vision is that these technologies let us take advantage of all the data that's being collected and synthesize that allows doctors, clinicians, administrators, and people in revenue cycle to all have the best possible information when they're doing their work. We want to make that extremely accessible and useful so that healthcare can be better."

AKASA believes that complexity in medical billing and reimbursement in the United States drives up hidden costs that we all pay, both in terms of dollars and in the erosion of trust people have that our healthcare system.

Under leadership from co-founders Malinka Walaliyadde, Varun Ganapathi, Andy Atwal and Ben Beadle-Ryby, AKASA is working to restore trust in the U.S. healthcare systemne of the reasons is because the leadership understands that automation alone is not the answer. To achieve maximum potential in transforming medical billing workflows, humans and machines must work together. AKASA's uses a unique, human-in-the-loop approach that flags outliers for human review, preventing bottlenecks common in other billing automation systems while also imbuing the entire automation process with human judgment and medical billing expertise.

In an interview with Varun Ganapathi, co-founder and CTO of AKASA, he explains how AKASA's technology works and optimize workflows within the revenue cycle by using AI-powered automation:

We 100% do our best to ensure that our customers can trust us. And some of the ways that we create that trust is leveraging our human-in-the-loop approach that helps us do the work we do. We're proud of that because one thing people don't realize about machine learning is that it has to be constantly maintained, and automation in general needs to be constantly maintained. As processes evolve, automation has to evolve in order to adapt to those changes. It's not like something you can just build once and it will work forever. Healthcare isn't static and change is inevitable. Things go wrong and you have to constantly keep fixing them.

And so the way we deploy our service is that it's a service. It's not a product that you buy and then you use it, and then we' disappear. You actually buy a service from us, and so we're continuously providing updating and improving service for you on the backend to ensure we're delivering for our customers everyday. If anything changes about the world, there are people on the backend noticing those changes and making fixes to the system so that those changes don't impact the daily operations of our customers."

The examples of how we create trust is through the fact that we accept that for anything you're automating, 80-90% of the work will be very straight forward. It's like highway driving, bringing in the self-driving caranalogy ut then there's always going to be unusual things that occur - we like to call them outliers. And so our system is designed around solving for those exceptions by ensuring that we have experts on hand to deploy to these outliers. The experts can solve the complex issue and teach our machines how to handle the outlier moving forward. In addition, we're always employing quality control to checkout work. So, rather than just deploying automation and not monitoring it all, we actually have people who are constantly spot checking like in a factory. They're always checking on what the automation is doing on a daily basis to ensure that our AI is performing perfectly all the time."

And now more than ever with COVID-19, AKASA's service is of an optimal need. "It's actually given us an opportunity to showcase a lot of the ways that the work we work we do is really beneficial. "Some examples include our deployment strategy with customers is completely remote. We don't need to actually send anyone on site to a health system to get our technology off the ground and running. All of our software can be operated in the cloud entirely.

"The second interesting thing is COVID-19 really showed is that billing volume can go up and down very rapidly. For revenue cycle teams, this can disrupt staff workflows n a very dynamic way,

And so as a health system, you're basically trying to simultaneously manage all of the incoming work and make sure you have the staff available to handle it. With automation, you can scale it up and down dynamically, So if there's a lot of claims to be processed, you can scale up the automation. When billing volumes dips, you could scale it down. And so it lets you essentially tie your expenses directly to your income, which is generally very helpful so you don't have these capital expenses that are just ongoing when balancing against incoming work. And the cool thing is when you can scale automation up and down like that, you can ensure that you're always optimizing 24/7e. You're not just getting really long backlogs, or you're not having people sitting around doing nothing. With COVID-19, there was a huge drop in patients seeking out elective and preventative care because people were afraid to go to the doctor or to hospitals. And then there was suddenly a lot more work once COVID-19 subsided for a bit. And so our customers have actually seen the benefit of AKASA's technology as when the workload suddenly increased. Our customers were able to scale up the automation and our technology took care of the increased workload for them."

"I've always been interested in healthcare. It's just a constant theme in my life that I've always cared a lot about it. I have relatives who are doctors, so I've always been interested in it but I chose to do machine learning and computer science as my personal focus. For years, I've been thinking about how can I bring machine learning to healthcare. I saw that physician burnout was a major issue due to having to deal with all of this administrative paperwork, and I noticed that administrative costs and healthcare continue to skyrocket. It seemed like the perfect place to employ machine learning as no one was even paying attention to the administrative side of healthcare because it's just not frankly as sexy a topic as the clinical side."

"There's all this boring paperwork and in order to actually solve for that, we have to become the experts in the boring stuff in order to make it so that our customers don't have to worry about it. But it seemed like the right thing to do because it could dramatically reduce costs of healthcare which don't touch the clinical side and improve the patient experience to prevent surprise bills that they don't understand, and then potentially go bankrupt as a result of that. And so, I personally became really interested in this area. It was extremely challenging because there are a lot of nuances in this space and there's a lot of complexity. That's why the opportunity exists is because of the complexity. The challenge ranged from how do you start from nothing but convince our initial customers to believe that you can actually provide a solution to solve their pain points. We overcame this by painting a vision of the dream that we wanted to create for them and finding some really innovative early customers like Sutter Health to embrace the vision."

"Along the way, there were a lot of challenges we needed to figure out on how to interface with all of these health systems. They're all built in different ways, and each customer has a slightly different situation. So we came up with the idea of employ machine learning and train it individually on each health system's data. Netflix and Google, of course, and YouTube, all personalize their systems, like their search engines, as they learn about you. But in the enterprise AI space, we do not see that happening very much, and it's actually extremely important in this particular area is that these AI solutions actually have to be personalized in some sense to the health system because they have to learn about the nuances of how that tailored to how each hospital and health systems works. I think that was one of our first great challenges - realizing that actually it was not going to be a one-size-fits-all approach, but we could use machine learning to essentially automate the process of making it fit for that particular customer. Another challenge was realizing that we needed people to be part of the system in order to ensure that mistakes never happened."

For more information or a free demonstration of their work, please visit their website at AKASA.com.

IMPACT

HOW DO YOU FARE?



IMPACT is the business analysis tool that facilitates examination of a business entity, for the expressed purpose of determining the next crucial steps essential to achieve their vision.

IMPACT's analysis provides deeper insight into the capability and suitability of providers' position in the new era of evolution within the tech market.

CONTACT GRANT BUTLER FOR MORE INFORMATION ON HAVING YOUR COMPANY'S IMPACT ANALYSIS DONE.

GRANTBUTLER@LIGHT4SOUL.COM

MEDTECH VISIONARIES AWARDS

BROUGHT TO YOU BY

LIGHT4SOUL